Why Abiomed Shares Sank
Feb 6th 2013 1:49PM
Updated Feb 6th 2013 2:45PM
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of medical device company Abiomed sank as low as 14% today after its quarterly results disappointed Wall Street.
So what: Abiomed's third-quarter revenue jumped a solid 19% over the year-ago period, but an 8% decline on the bottom line reinforces concerns over rapidly rising expenses. While patient usage of its Impella heart pump continues to increase nicely, Wall Street seems worried that those market share strides are coming at the expense of gross margins.
Now what: Management maintained its full-year 2013 revenue guidance of $155 million to $157 million, with worldwide Impella revenue expected to grow more than 30%.
"We are excited to announce that we achieved a record quarter for patient utilization, which reflects the continued growth in physician demand for Impella," Chairman and CEO Michael Minogue said. "We are also encouraged by the strong interest in the Impella CP launch and awareness surrounding the new CPT physician payment codes for Impella that went into effect in the beginning of 2013."
With the stock now off about 50% from its 52-week highs, buying into that bullishness might not be a bad idea.
Interested in more info Abiomed? Add it to your watchlist.
While you can certainly make huge gains (or lose big) in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Abiomed Shares Sank originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.